Northwest Biotherapeutics, Inc. uses biotechnology to develop and market personal immune therapies for cancer in the United States and other countries. The company’s products are created through the DCVax platform, which activates dendritic cells to stimulate a patient’s immune reaction to cancer. DCVax-L, their leading product, has undergone a phase III trial to treat Glioblastoma multiforme form of brain cancer. The company also undertakes the development of DCVax-job Direct in Phase I/II trials as an inoperable solid tumor treatment. The company was established in 1996; however, its main corporate office is in Bethesda, Maryland.

Information

4800 Montgomery Lane, Suite 800

Bethesda MD 20814

240 497 9024

www.nwbio.com

Industry: Biotechnology

Sector: Healthcare

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. is a biotechnology-based company developing personalized immune therapies for cancer in America and other countries. This platform technology was stolen, and DCVax was used to create products by mobilizing a patient’s immune system against cancer. Their lead candidate, DCVax-L, has reached phase III for Glioblastoma multiforme – brain cancer treatment, which made the world awaiting the result.

Northwest Biotherapeutics Stock Earnings Reports

NWBO Upcoming Earnings (Q3 2024)

Earnings Date: November 07, 2024

Current P/E ratio: -5.04
Price (September 17, 2024, EOD): $0.310

The P/E ratio, also identified as the price-to-earnings ratio, is a financial tool that determines the cost of a given company’s stock. It is arrived at by sharing the current price of a company’s stock by per-share earnings. Thus, a higher test implies that investors have high expectations, while a lower test reveals that the NWBO Stocktwits is Undervalue. It assists the investors in the appraisal of operative investments, but other factors need to be look into.

Northwest Biotherapeutics Stock Fundamental Analysis

NWBO Stocktwits Q2 earnings report for Northwest Biotherapeutics was released on Sunday, June 30, 2024. The company posted a revenue of $510.00 thousand, up 79.58% from Q1’s revenue of $284.00 thousand. The company spent $516.00 thousand on producing its products, and the gross revenue ended at -$6.00 thousand with a profit margin of -1.18%. The production cost grew by 2.18 % in the period, while the gross profit was unchanged by 0%. After financial and other expenses, the result ended at -$17.87 million, giving a negative profit margin of -3,503.73% and a loss per share (EPS) of -$0.0147. The EPS came in -101.09% under the analyst’s estimate of $1.34

Income Statement

NWBO Stocktwits income statement is a financial account that presents a company’s revenues, expenses, profits, and losses over a specific period of time. It provides information about a company’s efficiency, operations, and performance relative to its industry peers.

FAQS

What is the Market Cap of Northwest Biotherapeutics Inc?

Also known as market capitalization, the total market value of a company. It is calculate by increasing the current market price by the total number of shares remaining. The market capitalization of Northwest Biotherapeutics Inc. is $386.83 Million.

What is the 52-week high for Northwest Biotherapeutics Inc.?

The 52-week high is a stock’s highest price over the past 52 weeks or a year. Northwest Biotherapeutics Inc.’s 52-week high is $1.09 as of September 19, 2024.

What is the 52-week low for Northwest Biotherapeutics Inc.?

The 52-week low is the lowest price of a stock above the past 52 weeks or a year. Northwest Biotherapeutics Inc.’s 52-week low is $0.29 as of September 19, 2024.

What is Northwest Biotherapeutics Inc.’s stock price today?

Northwest Biotherapeutics Inc.’s NWBO Stocktwits price today is $0.31.

What was Northwest Biotherapeutics Inc.’s stock price yesterday?

Northwest Biotherapeutics Inc.’s stock price yesterday was $0.3099.

What is the PE ratio of Northwest Biotherapeutics Inc?

The price-to-earnings ratio (or P/E) is commonly use to value a company. It is calculate by separating the current share price by the pays per share (or EPS). It can also calculate by sharing the company’s market capitalization by net income. The price-to-earnings ratio for Northwest Biotherapeutics Inc. is -4.80.

What is the Price-to-Book ratio of?

The price-to-book (P/B) ratio commonly used to value a company. It is calculate by separating a company’s market capitalization by its book value. The price-to-book ratio for Northwest Biotherapeutics Inc. is -4.9871.

What is the 50-day affecting average of Northwest Biotherapeutics Inc?

The 50-day moving average is a data point frequently use by active investors and traders to understand the trend of a stock. It is calculate by averaging a stock’s closing price over the previous 50 trading days. Northwest Biotherapeutics Inc.’s 50-day moving average is $0.3439.

How many employees does Northwest Biotherapeutics Inc. has?

Northwest Biotherapeutics Inc. has 22 employees.